Daman Facility

Jump to

USFDA issues warning letter to USV Pvt over Daman plant

In a warning letter, the US Food and Drug Administration (USFDA) said the firm failed to establish laboratory controls designed to make sure components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity at its plant.
Alkem Labs falls 8% on 13 observations from USFDA for Daman unit

Alkem Laboratories shares fell over 8 percent intraday Friday on several observations from the US health regulator for Daman facility.
See FY17 margin at 17% with downside pressure: Alkem Labs

The company will work towards increasing volumes in the gastro-intestinal, anti-diabetic and cardio segments, among others, to overcome margin pressures due to industry headwinds, says Prabhat Agrawal, CEO of Alkem Laboratories.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Daman Facility

USFDA issues warning letter to USV Pvt over Daman plant

Alkem Labs falls 8% on 13 observations from USFDA for Daman unit

See FY17 margin at 17% with downside pressure: Alkem Labs